Insight on What Matters - So You Can Transform Your Business.
electing the right CRO to manage a clinical trial can be a critical decision in the program’s successful outcome. With so many CROs to choose from, what kind of evaluation criteria should be used?
Everything you need to know about the Federal Anti-Kickback Statute and the Beneficiary Inducement Statute and how it affects your patient engagement program.
The therapeutic field of adoptive cell therapy (ACT) in cancer has expanded dramatically in recent years, both in investment activity and technology proliferation. Tune in to our web panel discussion to find out what experts think is in store for this exciting field.
We recently sat with the experts at LMK Clinical Research Consulting to get their perspective on electronic Trial Master File (eTMF) challenges and best practices.
In light of our March 2017 web panel discussion, we sat down with Dr. Ravi Kiron, Managing Partner at Biopharm Strategy Advisors and moderator of the webinar, to find out whether this area could revolutionize the healthcare industry of the future or whether we are treading on dangerous ground that we know little about.
In this webinar, our speaker, Lucia Mokres, the Founder and Principal of Araneae Biotech Consulting, will examine the complexities of this scientific founder knowledge gap and explore why even when aware of this knowledge gap many founders are overwhelmed, resistant, unfamiliar, unaware, and unable to...
Precision medicine is a move away from a one-size-fits-all approach toward an approach with the goal to target the right treatments to the right patients at the right time.
Following are the top ten biopharma deals of 2019. For a comprehensive picture of all the prominent deals of 2019, download our 2019 Biopharma Partnering and M&A Year in Review Infographic.
In advance of the web panel discussion, we sat down with Linda Pullan to learn a little more about bispecifics and what you can expect to learn from the discussion.
The Promise and Challenges of Antibody-Drug Conjugates (ADC) Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drug that can ferry drugs into cancer cells while...